Science Translational Medicine | Levetiracetam Inhibits Aβ Production by SV2a-Dependent Modulation of APP Processing

This study reveals a novel mechanism by which the anti-epileptic drug Levetiracetam modulates APP metabolism via synaptic vesicle regulation in Alzheimer's disease, offering a translatable therapeutic strategy for early intervention in Aβ pathology, suggesting that SV2a could serve as a key node for drug development.

 

Literature Overview

The article titled 'Levetiracetam prevents Aβ production through SV2a-dependent modulation of App processing in Alzheimer’s disease models,' published in Science Translational Medicine, systematically investigates how the anti-epileptic drug levetiracetam (Lev) modulates the processing of amyloid precursor protein (APP) via synaptic vesicle protein SV2a, thereby inhibiting Aβ42 production. Using multiple animal models and human induced pluripotent stem cell (hiPSC)-derived neurons, combined with quantitative proteomics and stable isotope labeling, the study reveals that Lev redirects APP toward non-amyloidogenic pathways by modulating synaptic vesicle cycling—without directly inhibiting secretases. This finding provides new insights into early intervention strategies for Alzheimer’s disease (AD).

Background Knowledge

The core pathological features of Alzheimer’s disease (AD) are extracellular plaques formed by β-amyloid (Aβ) deposition and intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau. Aβ is generated through sequential cleavage of APP by β-secretase (BACE1) and γ-secretase, a process particularly active in acidic compartments such as early endosomes and synaptic vesicles (SV). Although current therapies can clear existing Aβ plaques, they fail to prevent continuous Aβ production, making upstream regulation of APP metabolism a critical therapeutic target.
Direct inhibitors of BACE1 or γ-secretase have been limited due to off-target effects and severe side effects, highlighting the urgent need for safer, selective intervention strategies. Research indicates that the subcellular localization of APP determines its cleavage fate: cleavage by α-secretase at the plasma membrane leads to the non-amyloidogenic pathway, whereas BACE1 cleavage in endocytic pathways promotes amyloidogenesis. Synaptic vesicles (SV), as key sites for activity-dependent Aβ release, directly influence APP localization and cleavage efficiency.
Prior work by the authors found that presynaptic protein degradation defects occur earlier than Aβ accumulation in APP knock-in mouse models, suggesting synaptic proteostasis dysfunction is an early event in AD. Therefore, targeting synaptic vesicle function (e.g., via SV2a) may reverse this process. This study explores whether Levetiracetam affects APP metabolism by modulating SV cycling, thus preventing Aβ pathology.

 

 

Research Methods and Experiments

The study employed multiple animal models for in vivo and in vitro validation, including AppNL-F/NL-F (NL-F), AppNL-G-F/NL-G-F (NL-G-F), and PDGFB-APPSwe/Ind (J20) transgenic mice, as well as human iPSC-derived cortical neuron models. Using a G76V-GFP reporter system to track protein degradation defects, combined with immunofluorescence, electron microscopy, and biochemical fractionation, the researchers confirmed Aβ42 enrichment within synaptic vesicle lumens, with protein accumulation preferentially occurring at presynaptic sites of excitatory synapses (VGluT1+).

To investigate Lev’s mechanism of action, the authors overexpressed familial AD-mutant APP (APPSwe/Ind) in primary neurons and used siRNA to knock down SV2a or SV2b. Results showed that Lev reduced levels of β-CTF and Aβ42, but this effect was abolished upon SV2a knockdown, confirming its dependence on SV2a. Furthermore, Lev’s inhibition of Aβ42 was validated in NL-F and NL-G-F mice as well as in hiPSC-derived neurons.

TMT-MS proteomic analysis revealed that Lev treatment significantly downregulated proteins associated with synaptic vesicle cycling, such as Syt1 and Rab5c. Live-cell surface labeling experiments demonstrated that Lev increases APP localization at the plasma membrane, promoting cleavage by α-secretase and thereby elevating sAPPα levels. Further use of ¹⁵N stable isotope labeling combined with mass spectrometry imaging directly proved that Lev reduces the production of newly synthesized Aβ42, rather than accelerating its clearance.

Key Conclusions and Perspectives

• Lev reduces β-CTF and Aβ42 production through an SV2a-dependent mechanism, identifying SV2a as a key pharmacological target and suggesting that SV2a agonists/modulators could represent a novel anti-Aβ strategy
• Lev decreases synaptic vesicle cycling rate, causing APP to remain longer at the plasma membrane, thereby promoting non-amyloidogenic processing—providing a theoretical basis for designing drugs that modulate APP subcellular localization
• In J20 mice, Lev mitigates synaptic loss and reduces mEPSC frequency, indicating it not only reduces Aβ production but also improves synaptic function, supporting its neuroprotective potential in early AD stages
• Premature presynaptic protein accumulation in brain tissue from individuals with Down syndrome, consistent with mouse models, strengthens the translatability of this mechanism to human AD-related pathology

Research Significance and Prospects

This study offers a new perspective for preventive treatment of Alzheimer’s disease: selectively inhibiting Aβ production by modulating synaptic vesicle dynamics rather than directly inhibiting secretases. Given that Lev is already FDA-approved and has a favorable safety profile, its repurposing for high-risk AD populations (e.g., individuals with Down syndrome) holds strong translational potential. Future large-scale clinical cohort studies should validate whether Lev can delay the progression from MCI to AD.

From a drug development standpoint, SV2a—as a membrane protein—has potential as a small-molecule target. Developing more selective SV2a modulators might avoid the sedative side effects of Lev while enhancing regulation of synaptic homeostasis. Moreover, combining Aβ-clearing antibodies (e.g., Lecanemab) with Lev-like drugs could enable a dual intervention strategy of 'clearance + blockade'.

 

 

Conclusion

This study systematically elucidates how Levetiracetam, via an SV2a-dependent mechanism, modulates synaptic vesicle cycling to redirect APP toward the non-amyloidogenic pathway, thereby preventing Aβ42 production at early disease stages. This finding not only reveals a causal link between synaptic proteostasis and Aβ pathology but also provides a readily translatable drug strategy for preventive intervention in Alzheimer’s disease. Given that Lev is widely used clinically with a well-established safety profile, early intervention trials in high-risk populations—such as individuals with Down syndrome or APOE4 carriers—are highly feasible. More importantly, this work establishes SV2a as a novel target for regulating APP metabolism, opening new avenues for next-generation anti-Aβ therapeutics. From bench to bedside, this mechanism-driven research paradigm underscores the importance of synaptic protection before irreversible neurodegeneration occurs, potentially reshaping Alzheimer’s disease care and ushering in an era of precision prevention.

 

Nalini R Rao, Ivan Santiago-Marrero, Olivia DeGulis, Anis Contractor, and Jeffrey N Savas. Levetiracetam prevents Aβ production through SV2a-dependent modulation of App processing in Alzheimer’s disease models. Science translational medicine.